OncoMed

OncoMed Pharmaceuticals, Inc.
Company type	Private (2004-13); Public (2013-19)
Traded as	Nasdaq: OMED
Industry	Pharmaceutical
Founded	University of Michigan
Founders	Michael Clarke; Max Wicha;
Defunct	April 23, 2019
Fate	Acquired by Mereo BioPharma
Headquarters	Redwood City, California, United States
Key people	Paul Hastings (CEO); John Lewicki (R&D chief); Chuck Alaimo (Operations director);
Revenue	US$24,700,000 (2012)
Total assets	US$207,600,000 (2016)
Number of employees	83 (2013); 47 (2007);
	Footnotes / references;

OncoMed Pharmaceuticals, Inc. was a public American pharmaceutical development company headquartered in Redwood City, California. The company was founded in August 2004 by two University of Michigan investigators, Michael Clarke and Max S. Wicha. As of 2013, the company had 83 employees. OncoMed's drug discovery work focuses on developing "targeted antibodies against cancer stem cells". The cancer stem cell technologies on which OncoMed depends are licensed from the University of Michigan where they were developed by the founders of the company. OncoMed went public in 2013 and was listed on NASDAQ under the stock symbol OMED. In April 2019 the company was acquired by Mereo BioPharma and delisted from the Nasdaq.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.